Claire Amos

8.6k total citations · 1 hit paper
31 papers, 1.8k citations indexed

About

Claire Amos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Claire Amos has authored 31 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Claire Amos's work include Prostate Cancer Treatment and Research (16 papers), Prostate Cancer Diagnosis and Treatment (8 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Claire Amos is often cited by papers focused on Prostate Cancer Treatment and Research (16 papers), Prostate Cancer Diagnosis and Treatment (8 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Claire Amos collaborates with scholars based in United Kingdom, Switzerland and New Zealand. Claire Amos's co-authors include Henry C Kitchener, Qinglan Qian, Peter Adamson, John Greenwood, Claire E. Walters, Pierre‐Olivier Couraud, Ruth Lyck, Britta Engelhardt, Nicholas D. James and Noel W. Clarke and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Claire Amos

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

2008 1.3k citations Henry C Kitchener, Qinglan Qian et al. The Lancet profile →

Peers

Countries citing papers authored by Claire Amos

Since Specialization

Citations

This map shows the geographic impact of Claire Amos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Amos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Amos more than expected).

Fields of papers citing papers by Claire Amos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Amos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Amos. The network helps show where Claire Amos may publish in the future.

Co-authorship network of co-authors of Claire Amos

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Amos. A scholar is included among the top collaborators of Claire Amos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Amos. Claire Amos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·Sarah Howlett, (unknown), Louise Brown, Claire Amos, Peter Dutey‐Magni, (unknown), Laura E. O’Shea, Catherine A. Hogan, Anna Wingate, (unknown), Rosalind A. Eeles, Michael Hubank, Phillip Williams, William Cross, (unknown), Nigel Clarke, (unknown), Nicholas D. James, Emily Grist, (unknown)	1
2	1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·Hassan Abdel‐Aty, Claire Amos, (unknown), (unknown), (unknown), Peter Dutey‐Magni, (unknown), Robert M. Bennett, (unknown), Ashutosh Sachdeva, (unknown), Laura Farrelly, David Matheson, (unknown), Patricia Díez, Olivia Naismith, (unknown), Gerhardt Attard, N. van As, Nicholas D. James	1
3	LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE 2024 ·Annals of Oncology ·(unknown), (unknown), Nicholas D. James, Ashwin Sachdeva, G. Attard, (unknown), (unknown), Omar El‐Taji, M. Varughese, Joanna Gale, Simon J. Brown, Narayanan Srihari, (unknown), David Matheson, Claire Amos, Claire Murphy, Christine McAlpine, (unknown), Louise Brown, (unknown)	6
4	Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047) 2024 ·European Urology ·Chris Parker, Noel W. Clarke, Adrian Cook, René Horsleben Petersen, Charles Catton, William Cross, Howard Kynaston, Raj Persad, Fred Saad, John Logue, Heather Payne, Claire Amos, L. Bower, Rakesh Raman, Ian Sayers, Jane Worlding, Wendy R. Parulekar, Mahesh Parmar, Matthew R. Sydes	5
5	1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT) 2024 ·Annals of Oncology ·(unknown), Hassan Abdel‐Aty, (unknown), (unknown), Peter Dutey‐Magni, (unknown), (unknown), Claire Amos, Iain Murray, (unknown), Nina Tunariu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nicholas D. James	1
6	1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials 2024 ·Annals of Oncology ·(unknown), Peter Dutey‐Magni, (unknown), Marina Parry, (unknown), (unknown), Anis Hamid, Claire Amos, William Cross, Silke Gillessen, Daniel M. Berney, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nicholas D. James, (unknown), Gerhardt Attard	3
7	The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer 2023 ·Clinical Oncology ·Hassan Abdel‐Aty, Laura E. O’Shea, Claire Amos, Louise Brown, Emily Grist, Gerhardt Attard, Noel W. Clarke, William Cross, Chris Parker, Max Parmar, (unknown), Nicholas D. James	4
8	1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE 2022 ·Annals of Oncology ·Áine Haran, (unknown), Thomas Hambrock, (unknown), (unknown), (unknown), Alex Hoyle, Ashwin Sachdeva, Sumia Ali, Claire Amos, Matthew R. Sydes, G. Attard, Max Parmar, Nicholas D. James, Noel W. Clarke	1
9	The importance of lymph node location, burden and treatment outcome in M1 HSPC: analysis from the STAMPEDE trial arms A and C 2020 ·European Urology Open Science ·Áine Haran, (unknown), (unknown), Thomas Hambrock, Claire Amos, (unknown), Nicholas D. James, (unknown), Matthew R. Sydes, Noel W. Clarke	1
10	634P Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison” of the STAMPEDE trial 2020 ·Annals of Oncology ·Áine Haran, Adnan Ali, Alex Hoyle, Thomas Hambrock, (unknown), Chris Brawley, Claire Amos, J. Calvert, Gerhardt Attard, Hassan Douis, Mahesh Parmar, Matthew R. Sydes, Nicholas D. James, Noel W. Clarke	2
11	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1\|RT Comparison” 2020 ·European Urology Oncology ·Adnan Ali, Alex Hoyle, Christopher Parker, Chris Brawley, Adrian Cook, Claire Amos, J. Calvert, Hassan Douis, Malcolm D. Mason, Gerhardt Attard, Mahesh Parmar, Matthew R. Sydes, Nicholas D. James, Noel W. Clarke	11
12	Managing Sick Leave in the University: Bureaucracy and Discretion 2020 ·PubMed ·Chrystal Jaye, Lauralie Richard, Claire Amos, Geoff Noller	1
13	SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt 2016 ·BMJ Open ·(unknown), Kofi A. Anie, Jacky B. Buckton, (unknown), Mark Layton, (unknown), Claire Hemmaway, (unknown), Claire Amos, Caroline J Doré, Brennan C Kahan, Sarah Meredith	4
14	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial 2012 ·Trials ·Matthew R. Sydes, Mahesh Parmar, Malcolm D. Mason, Noel W. Clarke, Claire Amos, John Anderson, Johann S. de Bono, David P. Dearnaley, John Dwyer, (unknown), Gordana Jovic, A.W.S. Ritchie, John M. Russell, Karen Sanders, George N. Thalmann, Nicholas D. James	100
15	Flexible trial design in practice: Dropping and adding arms in STAMPEDE (MRC PR08, CRUK/06/019)—A multiarm, multistage randomized controlled trial. 2012 ·Journal of Clinical Oncology ·Matthew R. Sydes, Nicholas D. James, Malcolm D. Mason, Noel W. Clarke, Claire Amos, John Anderson, Johann S. de Bono, David P. Dearnaley, John Dwyer, Gordana Jovic, (unknown), John M. Russell, Karen Sanders, George N. Thalmann, Mahesh Parmar, (unknown)	1
16	Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial 2011 ·Trials ·Matthew R. Sydes, Nicholas D. James, Malcolm D. Mason, Noel W. Clarke, Claire Amos, John Anderson, Johann S. de Bono, David P. Dearnaley, John Dwyer, Gordana Jovic, A.W.S. Ritchie, Martin Russell, Karen Sanders, George N. Thalmann, Mahesh Parmar	8
17	Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study breakdown → 2008 ·The Lancet ·(unknown), Henry C Kitchener, (unknown), Qinglan Qian, Claire Amos	1310
18	00094: ASTEC (SURGERY COMPONENT): A STUDY IN THE TREATMENT OF ENDOMETRIAL CANCER: A RANDOMISED TRIAL OF LYMPHADENECTOMY IN THE TREATMENT OF ENDOMETRIAL CANCER (ISRCTN 16571884) 2005 ·International Journal of Gynecological Cancer ·Henry C Kitchener, C. W. E. Redman, Ann Marie Swart, Claire Amos	12
19	Intracellular Domain of Brain Endothelial Intercellular Adhesion Molecule-1 Is Essential for T Lymphocyte-Mediated Signaling and Migration 2003 ·The Journal of Immunology ·John Greenwood, Claire Amos, Claire E. Walters, Pierre‐Olivier Couraud, Ruth Lyck, Britta Engelhardt, Peter Adamson	115
20	Ezrin and moesin co-localise with ICAM-1 in brain endothelial cells but are not directly associated 2002 ·Molecular Brain Research ·Ignacio A. Romero, Claire Amos, John Greenwood, Peter Adamson	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact